INTRODUCTION
Early colorectal cancer (CRC) and possible precursors do not result in any symptoms in the majority of cases. Screening of asymptomatic individuals therefore is necessary to detect more early cases and thereby ameliorate the prognosis of the disease.
The present short review will describe different asymptomatic population groups as well as different methods of screening. The latter have been evaluated with varying degrees of scientific evidence.
HIGH RISK POPULATIONS FAMILIAL POLYPOSES
Familial adenomatous polyposis (FAP) contributes with no more than 0.1 % of all CRC's in Denmark (1) as a result of an active register covering the whole country. Molecular genetic analysis is offered to first degree relatives of affected family members, and biennial sigmoidoscopy is performed from the age of about 10 years in confirmed gene carriers as well as those in whom no genetic diagnose has been reached (1). Colectomy with ileorectal anastomosis or ileoanal pouch is performed, when adenomas have been verified, but usually not before the age of 18-20 years. Ileo-anal pouch is preferred in most patients, as the cumulative risk of cancer in the rectal stump 40 years after IRA is 32 %, despite lifelong screening with proctoscopy (2).
The risk of duodenal cancer is 6 % in FAP patients, and screening with a duodenoscopy is suggested at intervals of 6 months-3years, depending on the severity of adenomatosis.
Gardner's and Turcot's syndromes and attenuated polyposis are all variants of FAP.
Peutz-Jeghers polyposis carries an increased risk of gastrointestinal cancer. Screening of the whole GItract is recommended at an interval of a few years, beginning in the second decade.
Juvenile polyposis might be inherited, and carries a lifetime risk of CRC of at least 10 %, suggesting screening with colonoscopy in these very rare families.
HEREDITARY NON-POLYPOSIS CRC (HNPCC)
The lifetime risk of CRC is over 80 % in gene carriers of this disease; half of the CRC's develop before the age of 50 and they represent 2-5 % of all CRC's.
HNPCC should be suspected, when three or more first degree relatives have CRC, endometrial cancer or small bowel cancer, one of which developed in persons less than 50 years of age. FAP must be excluded. Two mismatch repair genes seem to account for most cancers of HNPCC, but three germ line mutations have also been implicated. Genetic testing should be offered to all risk relatives in HNPCC families, in whom the specific family mutation has been found.
DNA testing should be performed in families with a strong likelihood of HNPCC and this type of screening is probably cost effective (3).
Most cancers are located in the right side, synchronous neoplasia is frequent (25 %) and the risk of metachronous CRC is about six times the risk in patients with sporadic CRC, and the adenoma-carcinoma sequence is more rapid (4).
Biennial colonoscopy is recommended from the age of 25 or 5 years earlier than the age of the youngest affected relative.
Subtotal colectomy is necessary when CRC is detected, and the rectal stump needs life long surveillance; however repeated colonoscopic polypectomy may reduce the incidence of CRC (5).
Establishment of countrywide registers may lead to earlier diagnosis and a better prognosis, but surveillance (screening) should include other organs like the uterus, stomach, small bowel and the urologic tract because of increased risk of cancers in these (6).
AND 2 FIRST DEGREE RELATIVES WITH COLORECTAL NEOPLASIA
A first degree relative with CRC means a 2-3 fold increase in risk of CRC (7), and two relatives increase the life time risk to 1 in 6. Overall, this type of familial CRC amounts to 10-20 % of all CRC's (8).
When index cases are diagnosed below 45 years of age, and more than one person is present, colonoscopy is the screening method of choice with intervals of 3-5 years, accompanied by yearly faecal occult blood testing (FOBT) (9). First degree relatives of patients with adenomas probably also have an increased risk of CRC, when the adenoma has been detected below the age of 60 (10) .
Individuals with one or two first degree relatives with colorectal neoplasia, not fulfilling the above criteria for screening with colonoscopy should be subjected to at least the same strategy as the average risk population above 50 years of age.
No prospective evaluation is available to support the above recommendations, and it should be remembered, that screening targeted solely at people with a family history will have little effect on mortality from CRC on the population level.
PREVIOUS CRC
Colonoscopic surveillance in 899 patients having had curative surgery for CRC has demonstrated a relative risk of 2.66 for metachronous CRC compared with the risk of initial CRC in a normal Danish population within a period of 18 years (11); it is not known to which degree, the incidence of metachronous CRC will be influenced by colonoscopic surveillance with polypectomy, but patients with synchronous colorectal neoplasia carrying the highest risk of metachronous CRC (12) should probably be subjected to more frequent colonoscopy (every 2 years) than those without (every 4-5 years).
Microsatellite instability might be considered a novel independent marker for predicting metachronous neoplasia (13) , allowing for a possible reduction in number of colonoscopies for surveillance.
Screening for recurrent CRC, locally as well as distant, has not been evaluated in proper RCT's, but two recent metaanalyses including 1,342 patients suggest that an intensive surveillance program detecting recurrence in an asymptomatic stage in a substantial proportion may result in a small survival benefit (12, 14) . More prospective studies are necessary to select the group of patients in whom the screening policy will be cost effective and the treatment of recurrence must be defined in detail.
ADENOMAS
These possible precursors of CRC are present in one third of individuals above 55 years of age (15) , resulting in a 2-8 fold increased risk of CRC compared with a normal population, but removal of the adenomas reduces the risk compared to that expected in the general population (16) . However, the optimal surveillance program has not been designed and the relative importance of initial polypectomy has not been quantitated.
Prospective trials are few and often with only a few years follow-up (17) . It has been suggested, that patients with no familial history of CRC and only single or small ( <10 mm) tubular adenomas can wait 10 years for their first surveillance colonoscopy, whereas all other adenoma patients should have their first follow-up colonoscopy no later than 3 years after the initial colonoscopy (18) .
The recommendations were based on experience with regular follow-up examinations in 1,159 patients between 1978 and 1996. A Danish adenoma surveillance program suggests that intervals of screening colonoscopy should be no more than 2 years in patients with sessile adenomas > 5 mm and villous adenomas (19) ; the prospective surveillance comprised 1-20 years.
Modelling risk of CRC based on polyp growth by year of surveillance has not been helpful so far (20) . CRC cannot be avoided in a surveillance program, but its prognosis may be similar to that in a screening program with FOBT's in an average risk population because of the more favourable staging of the CRC's detected (21) .
There is not solid scientific evidence for an upper age limit of colonoscopic surveillance of adenoma patients.
INFLAMMATORY BOWEL DISEASE
Ulcerative colitis: The risk of CRC is increased after 10 years pancolitis and a colonoscopic surveillance program with multiple biopsies may improve life expectancy by 7-14 months (22) . This may partly be explained by a higher compliance with long-term treatment with NSAID's in patients participating in surveillance (23) . No RCT's have been performed, evaluating the effectiveness of surveillance.
Crohn's disease: No evidence based recommendations are available in spite of a small increase in risk of CRC.
OTHER HIGH RISK GROUPS
No general recommendations have been given for patients with acromegaly and previous uretero-sigmoidoscopy, in spite of the well known risk of CRC (6).
AVERAGE RISK POPULATION
Population mass screening in asymptomatic persons above 50 years of age has not yet been met with success, in spite of good scientific evidence for reduction in mortality of CRC by screening annually or biennially by FOBT. Compliance has been low in Germany and Austria, the only two countries where screening has been offered on a national level. However, this may be explained by a poor organisation with no quality control. Recently, so called feasibility studies were set up in UK (24) and Australia to test whether the results from RCT's could be trans-formed to practice in limited areas of the countries, before the country wide screening was considered.
Other methods than FOBT's have not been evaluated to the same degree, and results from RCT's with initial endoscopy will not be available before some years from now.
FOBT'S Several case-control studies have suggested a reduced mortality from CRC by screening with FOBT's (25) , and 3 RCT's with the guaiac test Hemoccult-II (H-II) have confirmed this (Table 1) (25) . Colonoscopy was performed when blood was demonstrated in the stools. The American study used a modification of the H-II test (rehydrated), making it more sensitive for detection of blood, resulting in a higher sensitivity for detection of CRC, but with an accompanying fall in specificity, resulting in a substantial reduction of the predictive value of the test for CRC. The mortality ratio in persons screened at least once was 0.60 in the 2 European RCT's.
The Danish study showed a more pronounced reduction in mortality for tumours above the sigmoid colon (28 %), compared with 8 % below the descending colon (26) .
The American study has demonstrated a reduction in incidence of CRC, probably because of the very high colonoscopy rate, including polypectomy (28 % had a least one colonoscopy compared with 4.0 % and 4.3 % in the other biennial studies (25, 27) .
The rather low sensitivity of unhydrated H-II reduces the number of unnecessary colonoscopies and thereby the cost and risk of complications, but annual screening is preferable to biennial screening. A more sensitive test for blood is the HemeSensa, but its specificity is lower than that of the unhydrated H-II, making it less suitable for population screening. The same is true for immunochemical tests like HemeSelect, however testing might be reduced to 1 instead of 3 days, reducing sensitivity to a lesser de-gree, but increasing compliance. Such a policy would have to be evaluated in screening programs, using different cut-off points for levels of faecal haemoglobin (28) . Diagnostic accuracy may also be increased by the 2-tier principle, using the less specific test first (HemeSensa) and the more specific test (HemeSelect) in those with positive HemeSensa, but the procedure becomes more complicated.
The ongoing feasibility studies will show whether a satisfactory compliance (60 %) can be obtained as well as a favourable stage distribution (40-50 % Dukes' A); further more organisation problems may be solved, resulting in guidelines for the whole country.
Cost-effectiveness of a population screening program with unhydrated Hemoccult-II is considered to be higher than that of mammography as well as cervical smears in spite of a lower effectiveness for detection of the cancer (29) .
FLEXIBLE SIGMOIDOSCOPY
This 60 cm endoscopy (FS) has been recommended for many years to be repeated every 4-5 years in asymptomatic individuals aged over 50 (9), but more recently a one time FS has been suggested at age 60. A comprehensive review of FS has been published recently (25) , indicating that no more than 25 % of CRC's may be detected. Approximately 15 % of CRC's are diagnosed before year 60; acceptability of FS may be 50 % (an optimistic view), 50 % of all CRC's may be within the reach of the FS (again an optimistic view), and no more than 25 % of more proximal cancers may be found indirectly by colonoscopy as indicated by distal neoplasia.
Nevertheless, case-control studies have suggested a reduction in mortality from CRC, and a small RCT has demonstrated a significant reduction of incidence of CRC. Three RCT's are ongoing aiming to demonstrate a possible reduction of incidence of CRC, following polypectomy and immediate as well as sur- veillance colonoscopy in individuals with high risk adenomas (30) . The risk of intestinal perforation is very low, but FS is not completely without inconvenience to the individual, and FS may generate a considerable number of colonoscopies. In the UK trial (30), 12 % of the population would need colonoscopy because of adenomas, but the design of the trial only allowed for colonoscopy in the 5 % having significant adenomas ( >3, >1 cm, villous histology and severe dysplasia). Five colonoscopic perforations occurred in 2.142 individuals in connexion with polypectomy.
Cost effective analysis cannot be made before results of the large RCT's are available, but many countries will not have a sufficient number of doctors or experienced nurse endoscopists for screening with FS.
Unfortunately, no RCT's have been performed to demonstrate the possible benefit of adding FS once or repeatedly to a program with FOBT's. The slightly lower sensitivity of H-II in the left side of the colon might be compensated for by adding the FS (25) . A once FS alone cannot compete with a FOBT program, even when unhydrated H-II is used resulting in a program sensitivity of 59 % (31) , and the left to right shift in CRC distribution during recent years makes a once FS less attractive (32) . Adding simple screening with the most sensitive H-II (rehydrated) to a once FS increased the yield of significant neoplasia to a very minor degree (sensitivity increased from 70.3 to 75.8 %) (33) . COLONOSCOPY The disadvantages of colonoscopy as a primary screening instrument are so many, that most Europeans would not consider it suitable in average risk persons in spite of its higher diagnostic accuracy and the possibility of removing most precursors of CRC. A screening procedure should be simple, cheap, without harm or major inconvenience to the individual, and acceptable to the population targeted. None of these characteristics apply to colonoscopy. Nevertheless, studies have been performed in selected populations (34, 35) .
The risk of intestinal perforation makes colonoscopy unattractive (25) , but it has been suggested, that intervals of 10 years from age 50 to 60 might be cost effective (36) .
DOUBLE CONTRAST BARIUM ENEMA (DCBE)
This imaging procedure has not been evaluated as an initial screening procedure, but it has most of the disadvantages of colonoscopy and sensitivity as well as specificity for neoplasia is less (25) . COLONOGRAPHY Helical computerised tomography (CT) is combined with 3-dimensional imaging software that extracts and displays the mucosal surface. Bowel preparation still is necessary as well as air insufflation, both of which make the examination suboptimal for initial screening. Most studies have demonstrated a sensitivity for polyps >10 mm of at least 85 % and a specificity of 85-100 % (37) .
Magnetic resonance (MR) in stead of CT avoids the risk of radiation, but contrast medium is necessary.
Colonography (virtual colonoscopy) has not been evaluated for average risk screening, but may be used in patients with incomplete colonoscopy, being superior to DCBE.
OTHER SCREENING MARKERS
Calprotectin, a well known protein in granulocytes is present in increased concentration in faeces from patients with CRC, but the specificity is too low for screening average risk persons (38) .
Recently, it was suggested that immunocytochemical analysis of retrieved colonocytes might be used for screening purpose (39) .
Molecular stool screening using DNA markers still is experimental, but small clinical series clearly demonstrate the necessity of targeting multiple DNA alterations, and each marker must be specific to avoid too many non-beneficial colonoscopies (40) .
THE NEAR FUTURE
Guidelines should be developed at national levels on quality assurance of FOBT screening programs for the average risk population based on feasibility studies in limited parts of the country (41). This recommendation is followed by the UK, and results from 2 feasibility studies are awaited in 2002-3.
It should be foreseen, that endoscopy screening as well as radiologic and histopathologic services must expand.
Initial colonoscopy should be reserved for high risk groups. 
